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http:WHAT THIS PAPER ADDS
This is a contemporary review of clinical features, clinical scoring systems, and imaging parameters that have
been associated with an increased (or decreased) risk of early/late stroke in patients with symptomatic carotid
disease. Most, however, require independent validation before they can be applied to clinical practice.Objective: The aim of this review was to identify clinical and/or imaging parameters that are associated with an
increased (decreased) risk of early/late stroke in patients with symptomatic carotid disease.
In the ﬁrst 14 days: Natural history studies suggest that 8e15% of patients with 50e99% stenoses will suffer a
stroke within 72 hours of their index symptom. Currently, there are insufﬁcient validated data to identify highest-
risk patients for emergency carotid endarterectomy (CEA), but an increased risk of stroke appears to be predicted
by (i) an ABCD2 score of 4e7; (ii) the presence of acute cerebral injury on CT/MRI; (iii) Gray Scale Median (GSM)
<15, (iv) spontaneous embolisation on Transcranial Doppler (TCD); and (v) increased ﬂuorodeoxyglucose (FDG)
uptake in the carotid plaque on positron emission tomography (PET). A future goal must be to develop predictive
algorithms (based on accessible imaging strategies) for identifying acutely symptomatic patients with highly
unstable plaques for emergency CEA.
Medium to long term: In the randomised trials, about 70% of patients with symptomatic 70e99% stenoses were
stroke-free on “best medical therapy” at 5 years. Clinical predictors of increased stroke risk include (i) male
gender; (ii) age >75; (iii) hemispheric symptoms; and (iv) increasing comorbidity. Imaging features associated
with increased stroke risk include (i) irregular stenoses; (ii) contralateral occlusion; (iii) increasing stenosis
severity, but not subocclusion; (iv) tandem intracranial disease; (v) a failure to recruit intracranial collaterals;
(vi) low GSM; (vii) MR diagnosis of intra-plaque haemorrhage; (vii) spontaneous embolisation on TCD; and
(viii) increased FDG uptake in the carotid plaque on PET. Clinical/imaging parameters associated with a lower risk
of stroke include (i) female gender, especially those with 50e99% stenoses; (ii) ocular symptoms/lacunar stroke;
(iii) smooth stenoses; and (iv) chronic subocclusion.
 2015 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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//dx.doi.org/10.1016/j.ejvs.2015.01.011year risk of stroke (compared with best medical therapy
[BMT] alone) in patients with 50e99% stenoses who had
suffered carotid territory symptoms within the preceding 6
months.1,2 Since that time, a large amount of research has
been published in a wide range of scientiﬁc journals, across
a broad spectrum of medical disciplines, making it difﬁcult
for surgeons to remain appraised of potentially important
developments and innovations.
Two areas of clinical practice are currently of particular
interest in recently symptomatic patients. First, the risk of
stroke in the early period after onset of symptoms appears
514 A.R. Naylor et al.to be much higher than was previously thought, with
contemporary natural history studies suggesting that 8e
15% of patients with a 50e99% stenosis may suffer a stroke
within 72 hours of their index presenting symptom.3,4 This
type of patient was rarely (if ever) randomised within ECST/
NASCET and management strategies need to change to
deliver interventions as soon as possible after onset of
symptoms, accepting that beneﬁt must always be balanced
against the potential for increased procedural risk in some
patients. It would clearly be advantageous if it were
possible to develop and then validate accessible imaging
strategies that were capable of identifying a small propor-
tion of patients who would beneﬁt most from emergency
CEA or carotid artery stenting (CAS) within 72 hours of
onset of symptoms, as opposed to those with a lower im-
mediate stroke risk who could then undergo a delayed
intervention.
Second, despite showing signiﬁcant beneﬁt favouring
CEA, pooled data from ECST and NASCET5 (Table 1) reveal
that only 78 strokes would be prevented at 5 years per 1000
CEAs in patients with 50e69% stenoses (i.e. 922 [92%] were
ultimately unnecessary), compared with 156 strokes pre-
vented at 5 years in patients with 70e99% stenoses (i.e.
844 [84%] were ultimately unnecessary). Even if the pro-
cedural risk could be reduced to zero, the number of strokes
prevented at 5 years per 1000 CEAs in patients with 50e
69% stenoses would only increase to 162 (i.e. 838 [84%]
were still ultimately unnecessary), while only 218 strokes
would be prevented at 5 years in patients with 70e99%
stenoses if they underwent CEA with a 0% risk (i.e. 782
[78%]) ultimately unnecessary). In short, although any
strategy that reduces the procedural risk is to be welcomed,
this will have relatively little impact on increasing the
overall effectiveness of CEA in terms of late stroke pre-
vention. It would clearly optimise decision-making and
minimise exposure to avoidable risk, if clinical and/or im-
aging algorithms could identify a “high-risk for stroke”
cohort in whom to target CEA/CAS. This is particularly
important, as the concept of BMT has changed considerably
since the 1990s. It is worth remembering that BMT (at the
time of ECST/NASCET) was (at best) aspirin and smoking
cessation advice. High-dose statins were not available and
treatment goals for diabetes and hypertension were very
much different to what is considered normal practice today.
The aim of this topical review is to deliver an overview of
published data from the randomised trials (RCTs), as well as
contemporary, non-randomised studies to inform the
reader of clinical features, clinical scoring systems, andTable 1. Pooled individual patient meta-analysis of outcomes from the
Carotid Endarterectomy Trial, and the Veteran’s Affairs Study (data de
Stenosis severity 5-year stroke risk (%)
CEA BMT
<30% 18.36 15.71
30e49% 22.80 25.45
50e69% 20.00 27.77
70e99% 17.13 32.71
Near-occlusion 22.40 22.30imaging strategies that have been shown to predict a
greater (or lesser) risk of stroke, both in the hyperacute
period after onset of symptoms and in the medium to long
term.
THE RANDOMISED TRIALS
Table 1 summarises 5-year stroke rates (including periop-
erative stroke/death) in a meta-analysis of 6000þ patients
randomised to CEA or BMT within ECST, NASCET, and the
Veteran’s Affairs (VA) Study.5 While these trials are now
somewhat historical and aspects of management have
changed considerably (better medical therapy, emergence
of carotid artery stenting as an alternative to CEA, declining
procedural risks after CEA), there are still important ﬁndings
from the trials that are worthy of inclusion in this review.
Surgery conferred signiﬁcant beneﬁt in recently symp-
tomatic patients who had a 50e69% or a 70e99% stenosis,
measured using the NASCET method.5 Surgery conferred no
beneﬁt in patients with 0e49% stenoses, or in those with
“near-occlusion”. Near occlusion was deﬁned as a 90e95%
stenosis in the presence of collapse of the distal ICA lumen
on angiography.
Patients with 70e99% stenoses gained maximum beneﬁt
from CEA, but nearly 70% remained stroke-free on BMT at 5
years. Because >6000 patients were randomised within
ECST, NASCET, and the VA trials, it was possible to under-
take meaningful subgroup analyses.5e13 Although these
subgroup analyses are historical (i.e. the actual beneﬁts
accrued using modern BMT may have lessened the 5-year
stroke risks or beneﬁts from CEA), it is likely that the
messages (relating to age, gender, plaque irregularity, rapid
treatment, etc.) remain relevant in the current era.Predictive clinical parameters from the RCTs
Table 2 details clinical/imaging parameters that were
associated with a signiﬁcant increase in late stroke in the
randomised trials. Surgery conferred incremental beneﬁt
with increasing age.5e7 The highest absolute risk reduction
(ARR) was observed in patients aged >75 years (Table 2).
The beneﬁt conferred by CEA in patients aged <65 years
with 50e99% stenoses was relatively modest (ARR 5.6% at
5 years), compared with 8.6% for patients aged 65e74
years and 19.2% in patients aged >75 years. There was a
similar relationship between age and more severe carotid
disease. Carotid endarterectomy prevented 74 strokes at 5
years per 1000 CEAs in recently symptomatic patients aged
<65 years who had 70e99% stenoses, increasing to 173European Carotid Surgery Trial, the North American Symptomatic
rived from Rothwell et al.5).
ARR in stroke (%) Stroke prevented
per 1000 CEAs
2.6 0 @ 5 years
þ2.6 26 @ 5 years
þ7.8 78 @ 5 years
þ15.6 156 @ 5 years
0.1 0 @ 5 years
Table 2. Clinical and imaging features that were predictive of a signiﬁcant increase in late stroke in patients with 50e99% stenoses
randomised within ECST and NASCET.
Clinical features Imaging features
Increasing age5e7 Irregular versus smooth plaques5
5-year ARR in ipsilateral stroke conferred by CEA versus BMT 5-year ARR in ipsilateral stroke conferred by CEA versus BMTa
<65 years ¼ 5.6%; 65e74 years ¼ 8.6%; >75 years ¼ 19.2% smooth ¼ 8%; irregular ¼ 17%
Recent symptoms6 Increasing stenosis severity5
5-year ARR in ipsilateral stroke conferred by CEA versus BMT 5-year ARR in ipsilateral stroke conferred by CEA versus BMT
<2 w ¼ 18.5%; 2e4 w ¼ 9.8%; 4e12 w ¼ 5.5%; >12
w ¼ 0.8%
50e69% ¼ 4%; 60e69% ¼ 5.9%; 70e79% ¼ 15.8%; 80
e99% ¼ 17.7%; 90e99% ¼ 32.4%; near occlusion ¼ 0.1%
Male versus females6 Contralateral occlusion5
5-year ARR in ipsilateral stroke conferred by CEA versus BMT 5-year ARR in ipsilateral stroke conferred by CEA versus BMT
males ¼ 11.0%; females ¼ 2.8% contralateral occlusion ¼ 24%; no occlusion ¼ 13%
Hemispheric versus ocular symptoms6 Tandem intracranial disease9
5-year ARR in ipsilateral stroke conferred by CEA versus BMTa 3-year risk of ipsilateral stroke in medically treated patients
with IAD increased with ICA stenosis severity
ocular ¼ 5%; TIA ¼ 15%; stroke ¼ 18% 50e69% ¼ 19%; 70e84% ¼ 29%; 85e99% ¼ 45%
Cortical versus lacunar stroke11 No recruitment of collaterals10
3-year ARR in ipsilateral stroke conferred by CEA versus BMT 2-year ARR in ipsilateral stroke conferred by CEA versus BMT
non-lacunar stroke ¼ 15%; lacunar stroke ¼ 9% collaterals recruited ¼ 5%, no recruitment ¼ 19%
Increasing medical comorbidity2
2-year risk of ipsilateral stroke in medically treated patients
0e5 comorbidities ¼ 17%; 6 ¼ 23%; 7þ ¼ 39%
ARR ¼ absolute risk reduction; BMT ¼ best medical therapy; CEA ¼ carotid endarterectomy; IAD ¼ intracranial disease; ICA ¼ internal
carotid artery.
a 70e99% ICA stenoses.
Table 3. Ipsilateral carotid territory ischaemic strokes prevented
per 1000 CEAs at 5 years stratiﬁed for gender, stenosis severity,
and delay from randomisation to surgery (derived from a
reanalysis of data from Rothwell et al.6,14).
Time from
randomisation
50e69% stenosis 70e99% stenosis
All Males Females All Males Females
<2 weeks 148 152 138 230 235 417
2e4 weeks 33 68 57 159 238 66
4e12 weeks 4 50 22 79 183 22
>12 weeks 2.9 63 120 74 204 24
Symptomatic Carotid Disease 515strokes prevented in patients aged 65e74 years, while
surgery prevented 289 strokes per 1000 CEAs in patients
aged >75 years.13 This particular subgroup analysis remains
relevant in the modern era, if only to remind surgeons (and
stroke physicians) that age (alone) should never be used as
a reason to withhold CEA.
Males with 50e99% stenoses gained signiﬁcantly greater
beneﬁt from CEA than females5 (ARR in stroke at 5 years
conferred by CEA over BMT was 11% versus 2.8%, respec-
tively). Surgery also conferred a lower overall beneﬁt in
patients presenting with ocular symptoms (5-year ARR in
stroke conferred by CEA ¼ 5%), compared with TIA (ARR
conferred by CEA ¼ 15%) or stroke patients (ARR conferred
by CEA ¼ 18%).5 Patients presenting with cortical stroke
gained greater beneﬁt from CEA, compared with those with
lacunar stroke (ARR conferred by CEA at 3 years 15% versus
9%, respectively). However, the beneﬁt conferred by CEA in
lacunar stroke patients remained statistically signiﬁcant,5,11
Interestingly, NASCET also observed that increasing medical-
comorbidity (at baseline) was associated with an increased
risk of late stroke in medically treated patients, which was
not observed in patients with a similar number of comor-
bidities who were randomised to CEA.2 In their original
report, NASCET analysed 2-year rates of ipsilateral stroke,
relative to the presence/absence of certain baseline co-
morbid features including age >70, male gender, systolic BP
>160 mmHg, diastolic BP >90 mmHg, neurological event<30 days, stroke at presentation, stenosis >70%, irregular
stenoses and whether there was a past history of cardiac
failure, myocardial infarction, hypertension, hyper-
lipidaemia, diabetes, claudication, and smoking. Surgically
treated patients with 0e5 comorbid features had a 2-year
risk of ipsilateral stroke of 11%, declining to 8% in those
with 7þ comorbidities. By contrast, medically treated pa-
tients with 0e5 baseline comorbid features had a 17% risk
of ipsilateral stroke at 2 years, increasing to 39% in those
with 7þ comorbidities.2
One of the most important ﬁndings, however, from the
combined ECST, NASCET, and VA data was that CEA
conferred maximum beneﬁt if performed sooner (rather
than later) after onset of symptoms5,6,13,14 (Table 3). Pa-
tients (male and female) with a recently symptomatic 50e
516 A.R. Naylor et al.99% stenosis undergoing CEA <2 weeks of randomisation
had 148 strokes prevented/1000 CEAs at 5 years (ARR
14.8% at 5 years). Randomisation usually occurred within 1
week of symptom onset (Peter Rothwell, personal
communication). However; if surgery was delayed beyond
12 weeks, there was little evidence that any female patient
with a moderate stenosis beneﬁtted from surgery. Patients
with 70e99% stenoses who underwent CEA <2 weeks of
randomisation had 230 strokes prevented/1000 CEAs at 5
years (ARR 23%), compared with only 74 if surgery was
delayed >12 weeks (ARR 7.4%). In addition, there was clear
evidence of a difference in beneﬁt according to gender.
Males continued to gain beneﬁt from CEA, even if their
operation was delayed out to 12 weeks (Table 3). By
contrast, the beneﬁt conferred by CEA in females was
almost exclusively limited to those undergoing rapid sur-
gery, with no apparent evidence of beneﬁt after 4 weeks
had elapsed.6,13,14
An increasing number of modern practice guidelines now
use a 14-day threshold for delivering CEA,15,16 while some
have advocated a 48-hour threshold for treatment.17 Those
who still believe that delivering CEA within a 6-month
threshold remains acceptable may wish to reﬂect on an
alternative analysis of “delay data” from the ECST. Centres
who performed CEA in patients with 70e99% stenoses
within 50 days of onset of symptoms conferred an ARR in
stroke (compared with BMT) of 23.6% (95% CI 13.7e33.5).
This compares with an ARR of only 6.2% (95%CI 4.3e16.6)
in those centres where interventions were delivered after
more than 50 days had elapsed.18 It is a salutary fact,
therefore, that had ‘slower’ centres dominated the rando-
mised trials, CEA would probably not have shown signiﬁcant
beneﬁt.Predictive imaging parameters from the RCTs
A number of imaging features were associated with an
increased risk of late stroke in the RCTs5,8e10,13 (Table 2).
Plaque irregularity was associated with signiﬁcantly higher
rates of ipsilateral stroke in patients randomised to BMT,
compared with smooth stenoses. Surgery prevented about
100 strokes/1000 CEAs at 5 years in patients with smooth
stenoses, irrespective of whether the underlying stenosis
was 75%, 85%, or 95% (10% ARR). By contrast, surgery
prevented about 200 strokes/1000 CEAs at 5 years in pa-
tients with an irregular 75% stenosis (20% ARR), increasing
to 325 strokes prevented in patients with 85% irregular
stenoses (ARR 32.5%) and 541 strokes prevented/1000 CEAs
at 5 years in patients with an irregular 95% stenosis.5,8,13
When the RCTs recruited their patients, stenosis measure-
ment was based on intra-arterial angiography. This imaging
modality is now never used in routine clinical practice and it
remains to be seen whether an ultrasound or MR/CTA
diagnosis of plaque irregularity is capable of providing
similar prognostic information.
Late stroke increased with stenosis severity, but not near-
occlusion.5 This was an important ﬁnding, as “near-occlu-
sion” was previously thought to be a high-risk feature forstroke. The ARR in ipsilateral stroke at 5 years conferred by
CEA was 4% for patients with 50e59% stenoses, 6.0% for
patients with 60e69% stenoses, 15.5% for patients with
70e89% stenoses, and 32% for patients with 90e99% ste-
noses. Patients with chronic, near-occlusion gained no
beneﬁt from CEA. The reader should, however, exercise
caution before excluding all patients with suspected “near-
occlusion” from intervention. Most patients randomised
within ECST/NASCET had a considerable time delay between
symptom and surgery. In the modern era of intervening in
the hyperacute period after onset of symptoms (see later),
it is not uncommon to ﬁnd that Duplex ultrasound may give
misleading ﬁndings when performed very soon after the
index event.19 Despite the presence of high peak systolic
velocities across the stenosis, the sonographer may not be
able to easily visualise a lumen above the lesion (usually a
warning sign that there may be a near-occlusion). Corrob-
orative imaging (CTA/MRA) will nearly always show that the
ICA above the plaque is widely patent and amenable to
reconstruction.19 The key clue is the presence of high ve-
locities across the stenosis, as opposed to the high-
resistance low systolic velocities (and absent end-diastolic
ﬂow) usually seen in patients with a “conventional” near
occlusion.19
The presence of contralateral occlusion is associated with
a signiﬁcant increase in the risk of late stroke ipsilateral to
the treated ICA stenosis in medically treated patients.12,13
Surgery prevented 179 strokes at 2 years per 1000 opera-
tions in patients with 70e99% stenoses in the presence of a
<70% contralateral stenosis, increasing to 200 in patients
with a contralateral 70e99% stenosis. CEA conferred
maximum stroke prevention in patients with contralateral
occlusion (476 strokes prevented per 1000 operations).
Finally, tandem intracranial disease and a failure to re-
cruit intracranial collateral pathways were associated with a
signiﬁcant increase in late stroke in patients randomised to
medical therapy (Table 2). Interestingly, neither intracranial
disease, nor a failure to recruit collaterals was associated
with an increase in late stroke in patients randomised to
CEA.9,10ECST-2
Rothwell developed an algorithm, based on regression
analysis from the ECST/NASCET subgroup analyses, for
predicting the 5-year risk of stroke in medically treated
symptomatic patients with 50e99% stenoses, based on (i)
stenosis severity; (ii) plaque irregularity; (iii) clinical pre-
sentation; (iv) age; and (v) delay from most recent symp-
tom.20 The predicted 5-year rates of stroke for medically
treated patients ranged from <10% to >50% (Fig. 1). The
effectiveness of this algorithm in identifying a low to me-
dium risk cohort of symptomatic patients with 50e99%
stenoses (i.e. who might be treated medically in the future)
is currently being evaluated in the ECST-2 randomised trial
(www.ecst-2.com). Altaf et al. have recently reported that
this algorithm was not able to predict patients at higher risk
of suffering recurrent neurological events within a median
Figure 1. Predicted 5-year absolute risk of ipsilateral ischaemic stroke on medical treatment in ECST patients with recently symptomatic
carotid stenosis derived from a Cox model based on six clinically important patient characteristics. Reproduced with permission from
Rothwell PM, Mehta Z, Howard SC, Gutnikov SA, Warlow CP. From subgroups to individuals: General principles and the example of carotid
endarterectomy. Lancet 2005;365:256e265.
Symptomatic Carotid Disease 517of 30 days after onset of symptoms,21 although (to be fair)
the algorithm was never actually designed to identify high-
or low-risk patients within the ﬁrst few weeks.PREDICTING EARLY/LATE STROKE RISKS
The next sections provide an over-view of clinical features,
clinical scoring systems and imaging parameters from non-
randomised studies that have been associated with an
increased (or decreased) risk of stroke in the (i) hyperacute
period after onset of symptoms; (ii) in the ﬁrst 90 days; and
(iii) long term. Most (with the exception of the ABCD2 score)
have not been subjected to independent validation.Predicting stroke in the ﬁrst 14 days after onset
of symptoms
CEA confers maximum beneﬁt if performed sooner, rather
than later (Table 3), and there is also compelling evidence
that the early “natural history” risk of stroke after suffering
a TIA is higher than previously thought. Pooled data from
the ECST/NASCET/VA studies reported a 21% 5-year risk of
stroke in patients with 50e99% stenoses who were rand-
omised to BMT5 (Table 4). However, this 21% risk of stroke
at 5 years is at complete variance with the ﬁndings of seven
contemporary, natural history studies in TIA patients with
50e99% stenoses, where the risks of recurrent stroke were
Table 5. The ABCD2 scoring system (derived from Johnstone
et al.30).
Parameter Score
Age >60 years 1
<60 years 0
Blood pressure BP >140/90 mmHg 1
BP <140/90 mmHg 0
Clinical presentation Unilateral leg weakness 2
Speech impairment 1
Retinal 0
Duration of symptoms 60 minutes 2
10e59 minutes 1
<10 minutes 0
Diabetes mellitus Yes 1
No 0
Table 4. Risk of stroke in the hyperacute period after the index TIA
in patients with 50e99% carotid stenoses compared with pooled
data from the randomised trials.
48
hours
72
hours
7
days
14
days
5
years
ESCT þ NASCET þ VA5
medical therapy
21%
Fairhead 200522 20%
Purroy 200723 10%
Ois 20094 17% 22% 25%
Bonifati 201124 8%
Johansson 201325 5% 8% 11%
Merwick 201326 8%
Marnane 20143 5%a 9%a 9%a 16%a
a Additional data provided by authors (personal communication).
518 A.R. Naylor et al.prospectively documented immediately after onset of
symptoms.3,4,22e26 These more recent studies observed
that the risk of stroke in the hyperacute period was 5e8%
at 48 hours,3,24,25 17% at 72 hours,3,4 8e22% at 7
days,3,4,24e26 and 11e25% at 14 days3,22,24,25 (Table 4).
Additional support for the plaque being acutely unstable in
the early period after onset of symptoms comes from two
recent audits where (despite the early introduction of BMT),
11e13% of CEA patients suffered recurrent symptoms prior
to expedited CEA; a clear reﬂection of the unstable nature
of the underlying plaques.27,28
The most obvious explanation for the discrepancy be-
tween the 21% 5-year stroke risk on medical therapy in the
RCTs and the 20e25% stroke risk at 14 days in the natural
history studies is that the randomised trials recruited most
of their patients some time after the highest risk period for
stroke had elapsed, that is the randomised trials recruited a
completely different cohort to those now being reported in
contemporary, natural history studies.
Accordingly, there is an important cohort of extremely
“high risk for stroke” patients who previously missed out on
interventions (because they suffered their stroke before
having a chance to be treated) who now require emer-
gency/expedited interventions. It is, therefore, imperative
that practices should change in order that aggressive BMT
and urgent/emergency CEA can be delivered to the highest
risk patients in the ﬁrst few days after onset of symptoms.
This is quite a logistical undertaking and it would clearly be
beneﬁcial if there were validated algorithms for triaging the
highest risk patients for emergency CEA, as opposed to
deferred CEA. Interestingly, a parallel change in practice has
already occurred in patients with acute ST-segment eleva-
tion myocardial infarction, with a drive towards undertaking
primary coronary angioplasty/stenting as soon as possible
after onset of symptoms.29
Clinical scoring systems for predicting early recurrent
stroke.
ABCD2 score and its modiﬁcations
The ABCD2 score30 is a simple bedside scoring system that
was developed for TIA patients seen in primary care
(Table 5), based on age, blood pressure, clinicalpresentation, duration of symptoms, and presence/absence
of diabetes. The score ranges from 0 to 7.
An ABCD2 score of 0e3 is associated with a 1% risk of
stroke at both 48 hours and 7 days. Patients with an ABCD2
score of 4e5 had a 4% risk of stroke at 48 hours, increasing to
6% at 7 days, while an ABCD2 score of 6e7 was associated
with a 48-hour stroke risk of 8%, increasing to 12% at 7
days.30 It is not logistically possible to see every suspected
TIA patient within 24 hours of onset of symptoms and,
accordingly, most rapid-access TIA clinics triage their patients
using the ABCD2 score. Patients with an ABCD2 score of 0e3
are seen within 7 days, with protocols advising that all pa-
tients be started on aspirin and a statin before being seen in
the clinic. Higher-risk patients (ABCD2 score 4e7) are started
on antiplatelet and statin therapy and are then triaged to be
seen within 24 hours. One might have expected that a high
ABCD2 score would also be associated with a higher preva-
lence of signiﬁcant carotid disease on Duplex ultrasound.
However, that has not been found to be the case.31
In the ﬁrst modiﬁcation to the ABCD2 score, it was hy-
pothesized that the inclusion of acute cerebral infarction on
CT/MRI might identify a subgroup of higher-risk patients.
This became known as the ABCD2-I score32 (I denoting im-
aging; Table 6). Note that patients with any ABCD2-I score in
the absence of CT/MRI infarction faced a low risk of
recurrent stroke at 48 hours and 7 days. By contrast, the 7-
day risk of stroke increased to 9e15% in patients with an
ABCD2-I score of 4e7 in the presence of acute infarction.
Further revisions to the ABCD2 and ABCD2-I scoring sys-
tems were prompted by awareness that early stroke was
increased in patients presenting with (i) a dual TIA (deﬁned
as a TIA preceded by another TIA within the preceding 7
days); and (ii) a 50e99% stenosis of the ipsilateral internal
carotid artery. The revised ABCD3 scoring system allocated 2
points for dual TIA (maximum ABCD3 score ¼ 9), while the
ABCD3-I score added 2 points for acute infarction on CT/MRI
and 2 points for a >50% carotid stenosis (maximum ABCD3-I
score ¼ 13).33 Table 6 indicates how these modiﬁcations
inﬂuenced 7-day stroke rates. In essence, the higher the
score, the greater the 7-day risk of stroke. However, at ﬁrst
sight, there does not seem to be much advantage in knowing
whether there was a signiﬁcant carotid stenosis in addition
Table 6. The ABCD2, ABCD2-I, ABCD3 and ABCD3-I scoring systems
for predicting early stroke after a TIA.
Scoring system Stroke risk after TIA
48 hours 7 days
ABCD2 0e331 1.0% 1.2%
ABCD2 4e531 4.1% 5.9%
ABCD2 6e731 8.1% 11.7%
ABCD2-I 0e3 no infarction33 0.2%
ABCD2-I 4e5 no infarction33 1.4%
ABCD2-I 6e7 no infarction33 3.3%
ABCD2-I 0e3 acute infarction33 2.3%
ABCD2-I 4e5 acute infarction33 8.9%
ABCD2-I 6e7 acute infarction33 15.0%
ABCD3 0e334 1.0%
ABCD3 4e534 2.5%
ABCD3 6e934 11%
ABCD3 I 0e334 1.0%
ABCD3-I 4e734 4.0%
ABCD3-I 8e1334 10%
Symptomatic Carotid Disease 519to the presence of acute cerebral infarction. The most likely
reason for this discrepancy is because of a paucity of carotid
stenosis data. Most TIA patients underwent MRI/CT within
48 hours of symptom onset, but relatively few underwent a
carotid scan during this very early time period (i.e. absence
of evidence is not evidence of absence).
Imaging and the prediction of early recurrent stroke.
Numerous studies have correlated imaging-based features
with the presence/absence of a “vulnerable” carotid pla-
que, but very few have demonstrated whether these plaque
features were then associated with an increased risk of
stroke during early or late follow-up.
Marnane reported that 27% of ﬁrst-ever TIA patients with
50e99% stenoses suffered a recurrent stroke within 28 days
of symptom onset and correlated patterns of plaque his-
tology with those who did (and did not) suffer an early
recurrent stroke.3 One-ﬁfth of recurrent strokes occurred
within 48 hours of the index event, 33% happened within 7
days, while two-thirds occurred within 14 days. Marnane
observed that the plaques of patients with early recurrent
stroke had histological features consistent with marked
plaque instability, including extensive macrophage and
lymphocyte inﬁltration, low ﬁbrous content, extensive
ﬁbrous cap disruption, and neovascularisation. After
multivariate analysis; the only independent predictor for
early recurrent stroke was heavy macrophage inﬂamma-
tion.3 Interestingly, more traditional “plaque instability”
features such as a lipid rich core, luminal thrombus, and
intraplaque haemorrhage (IPH), were not associated with
an increased risk of recurrent stroke.3
The key issue, therefore, will be whether it is possible to
develop validated (but above all) accessible imaging stra-
tegies for identifying “high-risk for stroke” patients withacutely unstable plaques shortly after admission. To date,
very few studies have speciﬁcally looked at this role.
Computerised carotid plaque ultrasound
Salem reported that the presence of a large lipid core and a
GSM <25 were predictive of a signiﬁcantly increased risk of
recurrent neurological events in the 48e72 hour period
prior to expedited CEA, where patients underwent surgery
within a median of 8 days of the index symptom.27 In a
subsequent study involving blinded computerised ultra-
sound plaque analysis and blinded histological assessment of
126 CEA specimens, Salem observed (following logistic
regression) that two computerised plaque features were
associated with a high probability of there being a histo-
logically unstable carotid plaque: (i) plaque area >95 mm2;
and (ii) a juxta-luminal black area (JBA)>6 mm2.When these
plaque features were present together, there was a 90%
probability of an unstable plaque on blinded histology.34 To
date, this algorithm has not been tested in an independent
cohort. Russell et al. showed that plaque echolucency is
lowest when measured <30 days of the index symptom
(mean GSM 13), increasing to 22 at 31e90 days and 33 by
91e180 days,35 suggesting progressive plaque remodelling
and stabilisation Interestingly, this group also observed that
the GSM was signiﬁcantly lower (GSM¼ 15) in patients with
histologically unstable plaques, compared with histologically
stable plaques (GSM ¼ 32, p ¼ .01).
MRI
A number of studies have reported on the ability of MR to
predict patients at higher (or lower) risk of suffering a stroke
in the medium term (30e90 days) or in the long term.
Unfortunately, no-one has reported MRI-derived plaque
features that can identify patients at highest risk of suffering
a recurrent stroke in the ﬁrst few days after onset of
symptoms. An MRI diagnosis of IPH is, however, predictive
of increased spontaneous embolisation during the dissec-
tion phase of CEA,36 which does reﬂect plaque instability.
In a group of patients undergoing MRI within 48 hours of
their index cerebral event, Lindsay observed that MR fea-
tures associated with a Type VI American Heart Association
(AHA) unstable plaque (intra-plaque haemorrhage [IPH],
ﬁbrous cap rupture, or mural thrombus) were present in 54%
of patients, compared with 20% of asymptomatic subjects.37
While there was no mention of any correlation between
Type VI plaques and recurrent stroke, 78% of patients in the
acutely symptomatic group had an average of seven
ischaemic lesions on diffusion weighted imaging (DWI).
There was no association between AHA plaque type and the
prevalence of acute DWI lesions, but an MRI diagnosis of
ﬁbrous cap rupture was associated with a higher burden of
DWI lesions.37 This is clearly an area where carefully
designed MRI studies could inform the literature.
Transcranial Doppler ultrasound (TCD) diagnosed emboli-
sation
In a series of 123 recently symptomatic patients undergoing
expedited CEA, Salem observed that 43% of patients who
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spontaneous, preoperative embolisation on TCD, compared
with 22% who underwent CEA between days 8 and 14 and
16% in whom surgery was performed >14 days after the
index event.38 Almost a quarter (23%) of patients with
spontaneous embolisation suffered a recurrent neurological
event in the 48e72-hour period prior to expedited CEA,
compared with 11% of patients with no embolisation. The
key question remains as to what is the optimal duration of
TCD monitoring. In Salem’s study, patients were monitored
for only 30 minutes, which is probably too short for TCD
diagnosed embolisation to be validated as being a method
for identifying high risk for stroke patients in the ﬁrst few
days after onset of symptoms.
Positron emission tomography (PET)
Positron emission tomography (PET) tracers accumulate
within metabolically active cells. Fluorodeoxyglucose (FDG)
is a glucose analogue that actively competes with glucose
for uptake in macrophages, which will have increased rates
of glycolysis within the core of an unstable plaque. Because
FDG is not metabolised, it accumulates within the activated
macrophages. Marnane performed FDG-PET uptake studies
in 60 recently symptomatic patients and showed that pa-
tients with the highest tertile mean standardised uptake
value (SUV) of FDG in the ipsilateral (symptomatic) internal
carotid artery plaque had higher rates of early recurrent
stroke.39 Graebe et al. showed an inverse relationship be-
tween plaque GSM and FDG uptake. Echogenic plaques had
lower FDG uptake (suggesting less inﬂammation and greater
plaque stability). Interestingly, there was much more vari-
ability in the relationship between FDG uptake and the
GSM, that is low GSM (echolucent) plaques displayed a
range of inﬂammatory activity.40
However, one of the key problems with PET is its limited
accessibility and high costs. It is unlikely, therefore, that PET
will ever assume a role in routine clinical practice, but it
could prove very useful in validating/evaluating other more
accessible imaging modalities (e.g. MRI, computerised ul-
trasound plaque analysis) in identifying features associated
with a high risk of early stroke.
Predicting stroke in the ﬁrst 90 days after onset
of symptoms
Spontaneous embolisation on TCD
In a pooled analysis of two prospective databases (123
recently symptomatic patients) with a median 36-day
follow-up after onset of symptoms, the presence of spon-
taneous embolisation was associated with a threefold
excess risk of recurrent TIA/stroke (adjusted HR 3.35, 95% CI
1.69e6.67).22
MRI
There is stronger evidence correlating MR-derived plaque
features with recurrent stroke/TIA in the ﬁrst 30e90 days
after onset of symptoms. Altaf showed that an MRI diag-
nosis of IPH detected within a median of 19 days after theindex event was associated with a signiﬁcantly increased
prevalence of acute and subacute DWI lesions (OR 5.8,
95% CI 1.0e32.8), as well as a signiﬁcantly higher preva-
lence of TCD diagnosed spontaneous embolisation.41
Interestingly (and perhaps counterintuitively), there was
no association between spontaneous embolisation and
acute DWI lesions.
The same group has also reported that an MRI diagnosis
of IPH in recently symptomatic patients with 70e99% ca-
rotid stenoses (MR performed within a median of 40 days of
the index event) was associated with a signiﬁcant increase in
the prevalence of recurrent neurological events over the
next 30 days of follow-up. Cumulative freedom from recur-
rent events was approximately 85% in patients with no ev-
idence of IPH, compared with 50% in patients with an MRI
diagnosis of IPH.42 In their latest analysis, Altaf et al. re-
ported that patients with a combination of MRI diagnosed
IPH and spontaneous embolisation on TCD had the highest
rates of recurrent events during follow-up, although abso-
lute risks were not quoted in the paper, possibly because
they involved very small numbers.22
Positron emission tomography
Marnane performed FDG-PET uptake studies in 60 recently
symptomatic patients. The mean standardized uptake value
(SUV) of FDG in the ipsilateral (symptomatic) internal ca-
rotid artery plaque was signiﬁcantly higher in patients
suffering a recurrent stroke within 90 days of the index
event. The authors observed that a mean SUV of 2.14 had
98% speciﬁcity and 31% sensitivity for predicting recurrent
stroke, with 83% of patients with recurrent strokes being
above this SUV threshold.39Predicting late stroke in symptomatic patients
MRI
Teng performed high-resolution MR within 72 hours of the
index event in 42 patients with 30e69% carotid stenoses.
Twenty-one had an MR diagnosis of juxtaluminal haemor-
rhage or thrombus (JLH/T), while 21 did not. During 2 years
of follow-up, 11/21 patients with JLH/T at baseline (52%)
suffered recurrent neurological events, compared with 0/21
(0%) with no evidence of JLH/T.43
Hosseini combined data from three prospective data-
bases involving 179 patients with a symptomatic 50e99%
carotid stenosis (symptoms <6 months) who underwent
high-resolution MR imaging within 6 weeks of the index
event.44 One-hundred and fourteen (64%) had MR evidence
of IPH. During a follow-up ranging from 1 day to 9 years, 62
patients suffered recurrent neurological events and 57
(92%) had MR evidence of IPH on the baseline study.
Twenty-six patients suffered a recurrent stroke during
follow-up and 25 (96%) had an MRI diagnosis of IPH. The
cumulative 5-year risk of any recurrent neurological event
was 85% in patients with a baseline MRI diagnosis of IPH,
compared with only 13% in patients without IPH.44 Unfor-
tunately, there are no studies looking at serial changes in
Symptomatic Carotid Disease 521MRI diagnosed IPH and whether these correlate with pla-
que stabilisation or symptoms.
CTA
Magge analysed outcomes in 315 patients suffering a recent
stroke who had a <70% carotid stenosis at baseline and
who then underwent a second CT angiogram (average 440
days later). They observed that age >75 years, the use of
antihypertensive agents and a maximum carotid plaque
thickness >4 mm identiﬁed 10/14 patients who subse-
quently suffered a recurrent stroke.45
Ultrasound
Gronholdt followed 135 recently symptomatic patients (<6
months of the index symptom) who had 50e99% ICA ste-
noses and observed that patients with a GSM below a mean
of 74 had a mean 4-year risk of ipsilateral stroke of 29%
versus 12% for patients with an echogenic (plaque GSM
>75). This translates into a threefold excess risk of ipsilat-
eral stroke at 4 years for patients with echolucent plaques
(OR 3.1, 95% CI 1.3e7.3), compared with patients with
echogenic plaques.46
Contrast enhanced ultrasound (CEUS) also provides an
accessible assessment of plaque neovascularisation and this
has been shown to correlate with spontaneous micro-
embolisation on transcranial Doppler ultrasound.47 It re-
mains to be seen, however, whether increased neovascularity
on CEUS a TCD diagnosis of spontaneous embolisation can
reliably diagnose a high-risk subgroup for late stroke.
Circulating biomarkers
Although a number of potential circulating biomarkers (in
relation to the vulnerable plaque) have been evaluated, very
few studies have correlated biomarker activity with late
stroke risk in symptomatic patients with carotid disease,
possibly because most patients undergo CEA. Lipoprotein
associated phospholipase A2 (Lp-PLA2) is a macrophage-
derived enzyme that metabolises low-density lipoprotein
into the pro-inﬂammatory metabolites lysophosphatidyl-
choline (LPC) and oxidised fatty acids. Increased levels of
Lp-PLA2 have been found in atherosclerotic plaques associ-
ated with thinned or ruptured caps, where this is mostly
localised to activated macrophages undergoing apoptosis in
the lipid rich necrotic core and ﬁbrous cap.48 The Northern
Manhattan Stroke Study reported that (compared with pa-
tients with the lowest quartile of Lp-PLA2 activity), patients
with the highest quartile of LpPLA2 activity were twice as
likely to suffer a late recurrent stroke (OR 2.54, 95%CI 1.01e
6.39).49 It remains unclear whether LpPLA2 activity has any
additional predictive value in the acute and long term in
patients with signiﬁcant carotid disease.
IN CONCLUSION
Symptomatic: ﬁrst 14 days
There is currently a paucity of validated data to enable
identiﬁcation of the highest-risk patients for emergency
CEA, but an increased risk of stroke in the hyperacute periodappears to be predicted by (i) an ABCD2 score of 4e7; (ii)
the presence of acute cerebral injury on CT/MRI; (iii) a GSM
<15; and (iv) spontaneous embolisation on transcranial
Doppler. This is an important area for future research so
that accessible and validated imaging strategies can be used
to identify which patients would beneﬁt from emergency
(as opposed to deferred) CEA or CAS.Symptomatic: <90 days and long term
Clinical predictors of increased stroke risk in the intermediate
to long-term include (i) male gender; (ii) age >75 years; (iii)
hemispheric symptoms; and (iv) increasing comorbidity. Im-
aging parameters associated with an increased risk of inter-
mediate or late stroke include (i) irregular stenoses, especially
with increasing stenosis severity; (ii) contralateral occlusion;
(iii) increasing stenosis severity; (iv) tandem intracranial dis-
ease; (v) a failure to recruit intracranial collaterals; (vi) low
GSM; (vii) an MR diagnosis of IPH; and (viii) increased
macrophage uptake of FDG. There are currently few pub-
lished data linking biomarker activity with an increased risk of
late stroke in patients with symptomatic carotid disease.
Clinical/imaging parameters associated with a lower inter-
mediate/late risk of stroke include (i) females, especially
those with 50e99% stenoses and any delay to treatment; (ii)
ocular symptoms/lacunar stroke; (iii) smooth stenoses; and
(iv) chronic near-occlusion.
At present, all patients with recently symptomatic 50e
99% stenoses are being considered for CEA or CAS. Even if
the procedural risk could be reduced to zero, the majority
will still undergo an (ultimately) unnecessary intervention. It
is to be hoped that future studies will lead to the devel-
opment of image-based algorithms for identifying a cohort
of low- to medium-risk (for stroke) patients who can be
treated medically, thereby releasing logistical and ﬁnancial
resources to optimise the delivery of emergency/expedited
CEA to the highest-risk patients.CONFLICT OF INTEREST
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